Physician profile
Husam Bakdash
NPI 1376500785
$4,120.50
in general payments reported to CMS, 2019-2025
22 companies · $542 in 2025
The $542 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $265 · 2021: $343 · 2022: $603 · 2023: $186 · 2024: $702 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,430.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,375.88 | 2021-2025 | Micra, Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| Medtronic Vascular, INC. | $907.98 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $353.88 | 2019-2025 | Wainua, Farxiga |
| Abbott Laboratories | $236.12 | 2019-2024 | Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $180.28 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $144.32 | 2019-2025 | |
| Pfizer INC. | $144.11 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $122.52 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $120.67 | 2019-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.49 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $80.01 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $59.42 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.66 | 2021 | |
| Amgen INC. | $44.33 | 2019 | |
| Merck Sharp & Dohme LLC | $40.50 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $39.26 | 2019-2020 | |
| Cvrx, INC. | $33.94 | 2024-2025 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $27.16 | 2019 | |
| Novo Nordisk INC | $24.07 | 2024 | Wegovy |
| Boston Scientific Corporation | $16.45 | 2022 | |
| Scpharmaceuticals INC. | $14.48 | 2023 | |
| Surmodics, INC. | $12.97 | 2023 | Pounce Venous Thrombectomy System, Pounce Thrombectomy System, Pounce Thrombectomy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Husam Bakdash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.